|
Oct 16
|
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
|
|
Oct 16
|
Exelixis Gets Favorable Ruling in Patent Litigation With MSN
|
|
Oct 15
|
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
|
|
Oct 15
|
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
|
|
Oct 15
|
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
|
|
Oct 15
|
Exelixis and MSD to trial cancer therapies together in clinical collaboration
|
|
Oct 14
|
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
|
|
Sep 26
|
2 Growth Stocks to Buy With Less Than $100
|
|
Sep 24
|
Exelixis, Inc.'s (NASDAQ:EXEL) institutional investors lost 4.0% over the past week but have profited from longer-term gains
|
|
Sep 5
|
Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound?
|
|
Sep 2
|
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
|
|
Aug 30
|
Zacks.com featured highlights Genpact, MPLX, Exelixis, Paramount Global and H&R Block
|
|
Aug 29
|
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
|
|
Aug 29
|
5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy
|
|
Aug 28
|
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
|
|
Aug 28
|
Has Exelixis, Inc.'s (NASDAQ:EXEL) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
|
|
Aug 26
|
Why Exelixis (EXEL) Might be Well Poised for a Surge
|
|
Jul 23
|
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
|
|
May 12
|
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
|
|
May 8
|
Just Say No to Drugs: 3 Pharma Stocks to Avoid
|